You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial

Citation Tools

Article menu
Download PDFPDF
Oral Presentations
Still’s disease
OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Ruperto N, Brunner H, Constantin T, et al
OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial
Annals of the Rheumatic Diseases 2013;72:A97-A98.